{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:25:31Z","timestamp":1790767531046,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.critrevonc.2019.03.001","type":"journal-article","created":{"date-parts":[[2019,3,12]],"date-time":"2019-03-12T12:23:19Z","timestamp":1552393399000},"page":"123-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Breast cancer risk of hormonal contraception: Counselling considering new evidence"],"prefix":"10.1016","volume":"137","author":[{"given":"Lino","family":"Del Pup","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4662-7944","authenticated-orcid":false,"given":"Giovanni","family":"Codacci-Pisanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedro","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.03.001_bib0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/01.AOG.0000178754.88912.b9","article-title":"Use of the levonorgestrel-releasing intrauterine system and breast cancer","volume":"106","author":"Backman","year":"2005","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annepidem.2014.11.004","article-title":"Oral contraceptives and menopausal hormone therapy: relative and attributable risks of cardiovascular disease, cancer, and other health outcomes","volume":"25","author":"Bassuk","year":"2015","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1158\/1055-9965.EPI-13-0944","article-title":"Oral contraceptives and breast cancer risk overall and by molecular subtype among young women","volume":"23","author":"Beaber","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0020","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1200\/JCO.2007.11.1179","article-title":"Oral contraceptives and breast cancer risk in the international BRCA1\/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS collaborating group","volume":"25","author":"Brohet","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0025","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/ijc.31266","article-title":"Progestin-only and combined oral contraceptives and receptor-defined premenopausal breast cancer risk: the Norwegian Women and Cancer study","volume":"142","author":"Busund","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2013.08.002","article-title":"The molecular etiology and prevention of estrogen-initiated cancers: Ockham\u2019s Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity","volume":"36","author":"Cavalieri","year":"2014","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0035","doi-asserted-by":"crossref","first-page":"e49312","DOI":"10.1371\/journal.pone.0049312","article-title":"Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmq022","article-title":"Hormonal contraception and risk of cancer","volume":"16","author":"Cibula","year":"2010","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0050","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet (Lond. Engl.)"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jsbmb.2017.10.009","article-title":"Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women","volume":"174","author":"de Sousa Almeida-Filho","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0060","series-title":"Proceedings of the ISGE Congress","article-title":"Breast cancer risk of hormonal contraception and hormone replacement therapy: how to counsel and reassure patients considering recent evidence","author":"Del Pup","year":"2018"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0065","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1097\/CAD.0000000000000050","article-title":"Nomegestrol acetate\/estradiol hormonal oral contraceptive and breast cancer risk","volume":"25","author":"Del Pup","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0070","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.contraception.2010.11.009","article-title":"Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer","volume":"83","author":"Dinger","year":"2011","journal-title":"Contraception"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10911-015-9340-5","article-title":"Steroid hormones, steroid receptors, and breast cancer stem cells","volume":"20","author":"Finlay-Schultz","year":"2015","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0080","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1055-9965.EPI-13-0298","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Gierisch","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0085","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clbc.2017.10.016","article-title":"Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history","volume":"18","author":"Grandi","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0090","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39289.649410.55","article-title":"Cancer risk among users of oral contraceptives: cohort data from the royal college of general practitioners\u2019 oral contraception study","volume":"335","author":"Hannaford","year":"2007","journal-title":"Br. Med. J."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0095","first-page":"1931","article-title":"Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review","volume":"22","author":"Havrilesky","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0100","first-page":"249","article-title":"Use of exogenous hormones and the risk of breast cancer: results from self-reported survey data with validity assessment","volume":"27","author":"Heikkinen","year":"2016","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0105","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1056\/NEJMe1709636","article-title":"Oral contraceptives and the small increased risk of breast cancer","volume":"377","author":"Hunter","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0110","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-10-0747","article-title":"Oral contraceptive use and breast cancer: a prospective study of young women","volume":"19","author":"Hunter","year":"2010","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0115","first-page":"1","article-title":"Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy","volume":"91","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2007","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ajog.2017.02.002","article-title":"Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners\u2019 Oral Contraception Study","volume":"216","author":"Iversen","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0125","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.4065\/81.10.1290","article-title":"Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis","volume":"81","author":"Kahlenborn","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0130","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1038\/bjc.2014.175","article-title":"Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis","volume":"110","author":"Kim","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3892\/mco.2017.1259","article-title":"Association between oral contraceptive use as a risk factor and triple-negative breast cancer: a systematic review and meta-analysis","volume":"7","author":"Li","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/emph\/eox009","article-title":"Oral contraceptives cause evolutionarily novel increases in hormone exposure","volume":"2017","author":"Lovett","year":"2017","journal-title":"Evol. Med. Publ. Health"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ijc.24738","article-title":"A case-control study on hormone therapy as a risk factor for breast cancer in Finland: intrauterine system carries a risk as well","volume":"126","author":"Lyytinen","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0150","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa013202","article-title":"Oral contraceptives and the risk of breast cancer","volume":"346","author":"Marchbanks","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0155","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"Morch","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0160","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/ERC-10-0076","article-title":"Hormonal contraception and risk of endometrial cancer: a systematic review","volume":"17","author":"Mueck","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0165","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.2018.0448","article-title":"Weighing the risks and benefits of hormonal contraception","volume":"319","author":"Peachman","year":"2018","journal-title":"JAMA \u2013 J. Am. Med. Assoc."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0170","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-012-2339-3","article-title":"Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis","volume":"137","author":"Pierobon","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0175","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1093\/jnci\/81.17.1313","article-title":"Prospective study of oral contraceptive use and risk of breast cancer in women","volume":"81","author":"Romieu","year":"1989","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-017-4491-2","article-title":"Does levonorgestrel-releasing intrauterine system increase breast cancer risk in peri-menopausal women? An HMO perspective","volume":"167","author":"Siegelmann-Danieli","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jsbmb.2017.11.003","article-title":"Reproductive factors, nutritional status and serum 25(OH)D levels in women with breast cancer: a case control study","volume":"175","author":"Sofi","year":"2018","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0190","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0195","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/jwh.2018.6985","article-title":"Hormonal contraceptive use among women of older reproductive age: considering risks and benefits","volume":"27","author":"Tepper","year":"2018","journal-title":"J. Women\u2019s Health"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0200","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/ijerph13101028","article-title":"Beneficial effects of UV-radiation: vitamin D and beyond","volume":"13","author":"Trummer","year":"2016","journal-title":"Int. J. Environ. Res. Publ. Health"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0205","series-title":"Medical Eligibility Criteria for Contraceptive Use, Medical Eligibility Criteria for Contraceptive Use","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.critrevonc.2019.03.001_bib0210","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ypmed.2013.08.026","article-title":"Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis","volume":"57","author":"Yin","year":"2013","journal-title":"Prev. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818302208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:29:59Z","timestamp":1760902199000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818302208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":42,"alternative-id":["S1040842818302208"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breast cancer risk of hormonal contraception: Counselling considering new evidence","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}